01 January 2008
Comparing graft function for tacrolimus- and cyclosporine-treated patients. A long-term comparative study involving nephrotoxicity markers
Z. Marchewka, J. Kuźniar, K. Falkiewicz, B. Szymańska, M. Zynek-Litwin, D. Patrzałek, A. Długosz, M. KlingerAnn Transplant 2008; 13(1): 43-43 :: ID: 880211
Abstract
Background: The study compares the effect of cyclosporine and tacrolimus treatment on the transplanted kidney.
Material/Methods: This is done by examining nephrotoxicity markers in urine: lysosomal enzymes of proximal tubular cells (NAG, NAG-B, GAL, b-Gr) and brush border enzymes (AAP, GGT). The study involved 120 CsA-treated and 99 TAC-treated patients. Patients groups were identified depending on the time since transplantation (I - up to 1 year after transplantation; II - 1-2 years; III - 2-3 years; IV - more than 3 years). The control group consisted of 31 healthy people. Urine marker levels for CsA- and TAC-patients were examined in each group. For each group the study focused on correlation between markers' density and graft function as well as between CsA and TAC whole blood levels and the enzymes activity.
Results: In TAC group the time from transplantation was found to correlate negatively with creatinine level. No such association was found for CsA-treated group. NAG and NAG-B urine activity was significantly lower in control group. Peak enzyme activity for both CsA- and TAC-treated patients occurred in group I. As for groups III and IV, NAG-B excretion was found higher for the CsA group. NAG activity in urine and serum creatinine level were correlated significantly in CsA group (p<0.05). Similar correlation was found in TAC-group, but it was not significant. NAG urine activity was shown to correlate negatively with the time after transplantation (p<0.001) in TAC group.
Conclusions: The study favours tacrolimus-based treatment.
NAG and NAG-B appear to be the best CsA and TAC nephrotoxicity markers.
Keywords: Cyclosporine, Tacrolimus, Cerebral Palsy, Factor V Leiden mutation, Prothrombin G20210A mutation,
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






